Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:CEO |
Daniel J. Moore
|
| gptkbp:countryOfOperation |
gptkb:United_Kingdom
|
| gptkbp:focusArea |
cardiovascular
neuromodulation |
| gptkbp:formedByMergerOf |
gptkb:Cyberonics
gptkb:Sorin_Group |
| gptkbp:foundedYear |
2015
|
| gptkbp:fullName |
LIVN Worldwide, Inc.
|
| gptkbp:headquartersLocation |
gptkb:London,_United_Kingdom
gptkb:Houston,_Texas,_United_States |
| https://www.w3.org/2000/01/rdf-schema#label |
LIVN
|
| gptkbp:industry |
medical devices
|
| gptkbp:ISIN |
GB00BYMT0J19
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:marketCap |
multi-billion USD (as of 2023)
|
| gptkbp:numberOfEmployees |
~4000
|
| gptkbp:products |
neuromodulation devices
cardiac surgery devices heart failure devices |
| gptkbp:stockSymbol |
gptkb:LIVN
|
| gptkbp:website |
https://www.livanova.com/
|
| gptkbp:主要业务 |
medical device
|
| gptkbp:bfsParent |
gptkb:LivaNova
|
| gptkbp:bfsLayer |
7
|